MedTrace Logo

Pharmacokinetic Study of Oligonucleotides in Maixuekang Capsules

NCT06823895 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-02-12

No results posted yet for this study

Summary

The objective of this clinical trial is to learn the sequence and expression level of Maixuekang oligonucleotides in the plasma of healthy volunteers.

1. Detecting the sequence and expression levels of oligonucleotides in the blood of healthy subjects before and after a single administration of Maixuekang at different time points.
2. Detecting the sequence and expression levels of oligonucleotides in the blood of healthy subjects before and after multiple administrations of Maixuekang at different time points.

Single dose group: Participants will be given Maixuekang capsules once, 1g, orally.

Multiple dose group: Participants will receive 1g of Maixuekang capsules orally for 3 days, 3 times a day.

Conditions

  • Healthy

Interventions

DRUG

Maixuekang capsule

Single dose group: Participants will be given Maixuekang capsules once, 1g, orally. Multiple dose group: Participants will receive 1g of Maixuekang capsules orally for 3 days, 3 times a day.

Sponsors & Collaborators

  • Nanfang Hospital, Southern Medical University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-09-25
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06823895 on ClinicalTrials.gov